GH Research PLC ( GHRS ) reported an FY25 GAAP EPS of -$0.79. This was somewhat expected, as they’re still continuing investment in clinical development. The firm also managed to end the year with a decent cashI hold a Master’s degree in Cell Biology and began my career working for several years as a lab technician in a drug discovery clinic, where I gained extensive hands-on experience in cell culture, assay development, and therapeutic research. That scientific foundation gave me an appreciation for the r ...

Ardelyx (NasdaqGM:ARDX) 2026 Conference March 10, 2026 04:20 PM ET Company ParticipantsEric Foster - Chief Commercial OfficerLaura Williams - Chief Patient OfficerMike Raab - President and CEOSue Hohenleitner - CFOConference Call ParticipantsRoanna Ruiz - Senior Biotechnology AnalystRoanna RuizGlobal Healthcare Conference. My name is Roanna Ruiz. I'm one of the Senior Biotech Analysts here, and it is my pleasure to introduce the Ardelyx team with me. I've got the full lineup here. We've got Mike Raab, CEO, ...

Mechelen, Belgium; March 10, 2026, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received transparency notifications from Bank of America. Pursuant to Belgian transparency legislation1, Galapagos received transparency notifications from Bank of America Corporation on March 5 and 6, 2026. The initial notification indicates that Bank of America Corporation, as controlling entity, fell below the 5% threshold for equivalent financial instruments relating to Galapagos’ voting rights ...

PresentationGreat. Thanks, everyone. My name is Etzer Darout, senior biotech analyst at Barclays. It's my pleasure to have enGene with us this morning, CEO, Ronald Cooper. Ron, maybe if you can just give us an introduction of enGene for those that are less familiar with the story, and then we'd take it from there.Ronald H. CooperPresident, CEO & Director Well, enGene is a unique company with unique technology at actually a really unique time, right? So our technology is called the DDX platform. It's a propr ...

Market Overview - The trading day ended with major indices mostly unchanged, with the Dow Jones Industrial Average down about 34 points (less than 0.1%), the S&P 500 down about 14 points (0.2%), and the Nasdaq composite slightly up by about 1 point [7][8]. - The overall market sentiment was negative, with 356 S&P 500 names losing ground compared to 147 gaining [8]. Sector Performance - Only two sectors were in the green, while nine sectors were in the red, mirroring the previous day's performance [9]. - Communication services rose by about 0.3%, while energy fell by about 1.3% [9]. Notable Gainers - Vertex Pharmaceuticals saw a significant increase of over 8%, attributed to positive late-stage trial results for a kidney disorder drug, which could potentially generate about $5 billion in sales if approved [10][11]. - Sienna, a communications equipment company, gained about 6% following analysts raising price targets by an average of 24% after its earnings report [12][13]. - Rivian's stock rose more than 4% after an upgrade from TD Cowan, with a new price target set at $20 [14]. Notable Decliners - Boeing's shares dropped more than 3% due to a wiring flaw found on its 737 Max, which will delay some deliveries [15][16]. - West Pharmaceutical Services experienced a decline of more than 5% after announcing the retirement of its long-term CEO [17]. - Centene's shares fell about 16% after the company projected a 35% decline in ACA marketplace enrollment due to expired federal subsidies [18]. Oracle Earnings - Oracle reported adjusted revenue of approximately $17.19 billion, exceeding estimates of $16.89 billion, with cloud revenue up 44% to $8.9 billion [21][22]. - The company raised its total revenue guidance to about $90 billion, which is higher than previous expectations [27][30]. - Oracle's stock rose about 7% in after-hours trading following the earnings report, indicating positive investor sentiment [30].

Summary of Zura Bio Conference Call Company Overview - **Company**: Zura Bio (NasdaqCM: ZURA) - **CEO**: Sandeep Kulkarni, co-founder, recently returned to the CEO role after Tourmaline Bio acquisition - **Founded**: 2022 - **Pipeline**: Three programs, with a focus on tibulizumab as the lead program [5][6][7] Key Programs and Developments - **Tibulizumab**: A bispecific antibody targeting IL-17 and BAFF, with potential first-in-class status - **Indications**: Focused on hidradenitis suppurativa (HS) and systemic sclerosis (SSc) - **Phase 2 Trials**: Two important readouts expected in 2026 and 2027 [6][10][12] Hidradenitis Suppurativa (HS) - **Mechanism**: Combines IL-17A blockade with BAFF inhibition, targeting multiple pathways to improve efficacy - **Clinical Data**: Previous studies showed high target engagement (98% for IL-17 and BAFF) [15] - **Trial Design**: TibuSHIELD study with 225 patients, randomized to two active drug arms and placebo, primary endpoint at week 16 [29][30] - **Expected Outcomes**: Aiming for a HiSCR75 delta of 20%-25% compared to placebo, reflecting clinically meaningful effects [30][42] Systemic Sclerosis (SSc) - **Opportunity**: No approved treatments for totality of SSc, presenting a significant market opportunity - **Trial Design**: TibuSURE study with 80 patients, focusing on modified Rodnan skin score and CT scans for lung function [60][62] - **Regulatory Flexibility**: Agency recognizes challenges in SSc, showing willingness for new treatment options [62] Market Context and Competitive Landscape - **Unmet Need**: HS affects approximately 8% of the population, with current treatment options being suboptimal [42] - **Competitive Edge**: Zura Bio's tibulizumab is positioned as a first-in-class drug targeting two different pathways, potentially offering a unique treatment profile [43][44] Additional Insights - **Placebo Response Management**: Over-enrollment in trials to mitigate placebo effects, careful site selection, and training for accurate measurement of clinical endpoints [38][39] - **Future Directions**: Data from phase 2 trials will inform phase 3 trial design, with a focus on refining treatment strategies based on patient responses [45][62] Conclusion Zura Bio is strategically positioned in the biotech space with its innovative approach to treating complex autoimmune disorders through bispecific antibodies. The upcoming phase 2 trial results for tibulizumab in HS and SSc will be critical in validating its therapeutic potential and shaping future development plans.

Question-and-Answer SessionWell, it's an exciting year for the company heading into the Angelman Phase III. But before we dive into that, maybe just to start off with as a commercial stage rare disease biotech, could you provide a high-level overview of the story?Eric CrombezChief Medical Officer & Executive VP Yes. Great. And thanks for having me. Great to be here. So just very briefly, founded in 2010, public in 2014. Founded by our current CEO, Emil Kakkis, with a real focus on rare disease and focusing ...

markets carry more geopolitical responsibility — the conflict involves US military assets, US political uncertainty about timelines, and US inflation data that is directly impacted by oil prices. International markets, particularly in Asia, were simply pricing out the worst-case oil shock after Trump's ceasefire signals. The KOSPI's 5% single-session move is the most dramatic expression of that relief trade. If the conflict resolves, international equities have more room to run on a relative basis than US b ...

The gene-editing firm said it intends to issue $350 million in convertible senior notes due 2031 in a private placement aimed at qualified institutional investors.Convertible Note OfferingCRISPR Therapeutics plans to sell the notes under Rule 144A of the Securities Act. The rule permits sales to institutional buyers without public registration.The company may also grant initial purchasers an option to acquire an additional $52.5 million of notes. Buyers can exercise that option within 13 days of the issuanc ...

(Investorideas.com Newswire) a go-to platform for big investing ideas, including biotech stocks issues a news and trading alert for Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions. The stock makes the Nasdaq top percentage gainers list today, currently trading at $1.02, up $0.48, with a day’s high of $1.17 on a volume of over 141 million shares as of this report.Longeveron announced ...